Trastuzumab Re-Introduction with FOLFIRI for Treatment of HER2 Overexpression-Advanced Gastric Adenocarcinoma Following Failure of Other Trastuzumab-Based Chemotherapy Regimens - Case Reports in Clinical Medicine

CRCM > Vol.4 No.4, April 2015

Volume 4, Issue 4 (April 2015)

ISSN Print: 2325-7075 ISSN Online: 2325-7083

Google-based Impact Factor: 0.2 Citations

Trastuzumab Re-Introduction with FOLFIRI for Treatment of HER2 Overexpression-Advanced Gastric Adenocarcinoma Following Failure of Other Trastuzumab-Based Chemotherapy Regimens ()

HTML XML

Download as PDF (Size: 526KB) PP. 131-136

DOI: 10.4236/crcm.2015.44028 4,378 Downloads 6,296 Views Citations

Author(s)

Olivier Dubreuil^1*, Aziz Zaanan², Olivier Pellerin³, Jean-Baptiste Bachet¹, Philippe Rougier², Julien Taieb²

Affiliation(s)

¹Gastro-Enterology and Digestive Oncology Unit, Pitie Salpetriere Hospital, Paris, Farnce.
²Digestive Oncology Unit, European Georges Pompidou Hospital, Paris, France.
³Paris-Descartes Medical University, INSERM U970, Interventionnal Radiology, European Georges Pompidou Hospital, Paris, France.

ABSTRACT

A 67-year-old man diagnosed with HER2 overexpression advanced gastric adenocarcinoma and metastasis to liver and lungs was admitted for tertiary care. He received a third line chemotherapy that consists of trastuzumab combined with FOLFIRI regimen (irinotecan plus 5-FU/LV) following a disease relapse after an initial successful response to a combination of 5FU + oxaliplatin and trastuzumab. The patient showed a favorable and prolonged response to it. In addition the chemotherapy was well tolerated and devoid of remarkable side effects. The response to trastuzumab + FOLFIRI was assessed clinically and through CT scan imaging and upper gastrointestinal endoscopy. This case report shows that firstly the combination of FOLFIRI and trastuzumab could be tested as another regimen in metastatic gastric cancer, and, secondly, that in this disease, like in metastatic breast cancer, the continuation of trastuzumab after an initial progression under this antibody could be tested in order to improve the efficacy of the treatment Trastuzumab re-introduction with FOLFIRI for treatment of HER2 overexpression-advanced gastric adenocarcinoma following failure of other trastuzumab-based chemotherapy regimens.

KEYWORDS

Stomach Neoplasm, Trastuzumab, Treatment Reintroduction

Share and Cite:

Dubreuil, O. , Zaanan, A. , Pellerin, O. , Bachet, J. , Rougier, P. and Taieb, J. (2015) Trastuzumab Re-Introduction with FOLFIRI for Treatment of HER2 Overexpression-Advanced Gastric Adenocarcinoma Following Failure of Other Trastuzumab-Based Chemotherapy Regimens. Case Reports in Clinical Medicine, 4, 131-136. doi: 10.4236/crcm.2015.44028.

Cited by

[1]	Is there any advantage from continuation of trastuzumab beyond progression in metastatic her positive gastric cancer? report of two cases and literature review
	INTERNATIONAL JOURNAL OF SCIENTIFIC RESEARCH, 2018

[2]	Is ther e any advantage from continuation of trastuzumab beyond progression in metastatic her positive gastric cancer? report of two cases and literatur e review
	2018

[3]	Is there any advantage from continuation of trastuzumab beyond progression in metastatic her positive gastric cancer
	2018

[4]	Trastuzumab in Combination with FOLFIRI in Patients with Advanced HER2-Positive Gastro-Esophageal Adenocarcinoma: A Retrospective Multicenter AGEO Study
	Targeted Oncology, 2017

[5]	Therapeutically Induced Changes in HER2, HER3, and EGFR Protein Expression for Treatment Guidance
	Journal of the National Comprehensive Cancer Network, 2016

Journals Menu

Follow SCIRP

	+1 323-425-8868
	customer@scirp.org
	+86 18163351462(WhatsApp)
	1655362766

	Paper Publishing WeChat

Journals Menu

Home

About SCIRP

Service

Policies